Wolverine Trading
CPRX

Wolverine Trading’s Catalyst Pharmaceutical CPRX Stock Holding History

Wolverine Trading’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,900
Closed -$215K – 4861
2024
Q2 		$215K Buy
+13,900
New +$216K ﹤0.01% 3773
2023
Q1 		– Sell
-36,700
Closed -$683K – 4334
2022
Q4 		$683K Buy
36,700
+21,700
+145% +$334K ﹤0.01% 2122
2022
Q3 		$191K Buy
+15,000
New +$178K ﹤0.01% 3644
2020
Q2 		– Sell
-12,000
Closed -$47K – 4653
2020
Q1 		$47K Buy
12,000
+200
+2% +$821 ﹤0.01% 4280
2019
Q4 		$43K Buy
+11,800
New +$55.2K ﹤0.01% 4487
2019
Q3 		– Sell
-14,900
Closed -$57K – 4412
2019
Q2 		$57K Buy
+14,900
New +$64.4K ﹤0.01% 4167
2018
Q4 		– Sell
-23,000
Closed -$87K – 4544
2018
Q3 		$87K Buy
+23,000
New +$72.1K ﹤0.01% 4584

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Wolverine Trading's CPRX Position: Q3 2024 in Review

Wolverine Trading sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 10,609 shares — an estimated $164K sold.

Wolverine Trading first reported a position in CPRX in Q3 2018 and held it in 7 quarters. The position peaked at $391K in Q4 2022. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Wolverine Trading reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Wolverine Trading sold 10,609 Catalyst Pharmaceutical shares in Q3 2024, an estimated $164K.
  • Wolverine Trading first reported a position in Catalyst Pharmaceutical in Q3 2018 and held it in 7 quarters.
  • Wolverine Trading's Catalyst Pharmaceutical position peaked at $391K in Q4 2022.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Wolverine Trading's 13F filing for Q3 2024, filed 14 Nov 2024.